TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02449525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion of flaps by a special bypass system
Description: Free flaps are perfused via a special bypass perfused by a new technique supported by a intermittent perfusion support system.
Study: NCT00474903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: Given orally
Study: NCT02986269

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spontaneous breathing(SB)
Description: general anesthesia across LMA under SB without PSV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing(SB)
Description: general anesthesia across LMA under SB without PSV
Study: NCT00474903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole magnesium
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole magnesium
Description: Given orally
Study: NCT02986269

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Support Ventilation
Description: general anesthesia across LMA under SB with PSV
Study: NCT01937507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAI with FOLFOX
Description: HAI with FOLFOX q 3 weeks
Study: NCT00880477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib vaccine
Description: Vaccination according to a 3-dose schedule at 1 ½, 3 ½ and 6 months of age with booster at 15-18 months of age.
Study: NCT00474903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole magnesium
Description: Given orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally
Study: NCT00880477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib vaccine
Description: Vaccination according to a 3-dose schedule at at 1 ½, 3 ½ and 6 months of age with booster at 15-18 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EngerixTM-B
Description: The vaccine was administered according to a 2-dose schedule at 1½ and 6 months of age with booster at 15-18 months of age.
Study: NCT01686906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bowman layer graft implantation
Description: For patients with progressive advanced keratoconus, a mid-stromal manual dissection is made and a donor isolated Bowman layer is positioned into the stromal pocket.
Study: NCT05125536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: rutin
Study: NCT01205555

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: urine LH testing
Description: The study group will start urine LH (LHu) testing according to the mean diameter of the leading follicle on ultrasound as per :~13mm or less - Repeat ultrasound scan in 1-2 days 14-17mm - start urine LH testing the evening of the day of the scan 18mm or greater - do one LHu test in the afternoon of the day of the scan before HCG administration Once the patient has commenced LHu testing she will perform 2 tests per day. The tests will be performed at 7am and 7pm. LHu testing will continue until the time of HCG administration or positive uLH.If the LHu result is positive either in the morning or afternoon, the insemination will be the next morning without the administration of exogenous HCG.~If the patient has an inconclusive LHu result, a blood LH test will be taken. If the LH blood test is negative (\<8 IU\\L) she will continue testing LHu. If the LH blood test is positive (≥ 8 IU\\L) the insemination will be the next day.
Study: NCT04412382

Intervention type: DIAGNOSTIC_TEST
Intervention: NETosis markers
Description: NETosis markers (Cf-DNA. MPO-DNA, Cit-H3) and the cytokines IL-6 and IL-1β will be analyzed from the subjects' plasma.~Spittle sample (or bronchoalveolar fluid if necessary for diagnostic-therapeutic purposes) will be collected and the detection of NETs at electron microscopy will be assessed.

Intervention type: DIAGNOSTIC_TEST
Intervention: NETosis markers
Description: NETosis markers (Cf-DNA. MPO-DNA, Cit-H3) and the cytokines IL-6 and IL-1β will be analyzed from the subjects' plasma.~Spittle sample (or bronchoalveolar fluid if necessary for diagnostic-therapeutic purposes) will be collected and the detection of NETs at electron microscopy will be assessed.
Study: NCT04039633

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Burst Spinal Cord Stimulation
Description: Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Burst Spinal Cord Stimulation
Description: Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham spinal cord stimulation
Description: A pulse generator is implanted, but no spinal cord stimulation is provided

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham spinal cord stimulation
Description: A pulse generator is implanted, but no spinal cord stimulation is provided
Study: NCT01534234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PARADYM RF SONR
Description: SonR CRT Optimization

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PARADYM RF SONR
Description: Echocardiography Optimization
Study: NCT03838068

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: Biodentine is considered a calcium silicate cement

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mineral trioxide aggregate
Description: calcium based silicate cement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervical pulpotomy
Description: coronal pulp tissue was removed till the orifice

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical pulpotomy
Description: coronal pulp tissue was removed till the orifice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Anesthetics Procaine
Description: 40 mg/0.01 mg/ml contains sodium metabisulfite and sodium and articaine as an active substance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetics Procaine
Description: 40 mg/0.01 mg/ml contains sodium metabisulfite and sodium and articaine as an active substance
Study: NCT01136421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium bromide
Description: Patients received ipratropium bromide (IB group, 0.5 mg in 3 mL of normal saline) delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, patients received intravenous placebo (10 mL of normal saline). Thereafter 4 doses of nebulised IB with terbutaline are administered at 30 min intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Patients received magnesium sulfate (MgSO4 group, 150 mg in 4 mL of normal saline)delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, additional magnesium sulfate is given as an intravenous bolus (1.5g in 10 ml). Patients received thereafter 4 doses of nebulized magnesium sulfate with terbutaline at 30 min intervals.
Study: NCT04591795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sahastara remedy extract
Description: The concentration of SHT extract is 100 mg per capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Diclofenac sodium, 25 mg enteric-coated tablets
Study: NCT02130258

Intervention type: DEVICE
Group type: OTHER
Intervention: Quantitative Sensory Testing (QST)
Description: Subjects will undergo hot and cold temperature testing using the QST device at two points: 1) Before ESI and 2) after ESI.

Intervention type: DEVICE
Group type: OTHER
Intervention: Quantitative Sensory Testing (QST)
Description: Subjects will undergo hot and cold temperature testing using the QST device at two points: 1) Before ESI and 2) after ESI.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Epidural Steroid Injection (ESI)
Description: Subjects will receive an ESI by their clinical physician as part of their clinical treatment. This procedure is not given as part of the research study.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Epidural Steroid Injection (ESI)
Description: Subjects will receive an ESI by their clinical physician as part of their clinical treatment. This procedure is not given as part of the research study.
Study: NCT03596268

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: 3T Prisma MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: 3T Prisma MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Laboratory Tests
Description: Blood (plasma and cellular) will be collected.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Laboratory Tests
Description: Blood (plasma and cellular) will be collected.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lumbar Puncture
Description: CSF will be collected

Intervention type: DIAGNOSTIC_TEST
Intervention: Lumbar Puncture
Description: CSF will be collected
Study: NCT04239586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: Starting treatment with sulfonylurea class of drug
Study: NCT04329793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assisted gait training with Walkbot System
Description: The experimental group will receive at least 3 treatment sessions per week consisting of 40 minutes in robot-assisted gait training with Walkbot System in addition to their usual Physical therapy sessions. In total, the number of Walkbot sessions will be 20, in uninterrupted weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: The control group will receive their usual Physical therapy sessions during 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: The control group will receive their usual Physical therapy sessions during 6 weeks.
Study: NCT05086159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: Weekly education sessions lasting approximately 30 minutes each, once a week for four weeks.~Session 1: the nervous system is like an alarm to protect.~Session 2: common ways the nervous system becomes sensitive.~Session 3: importance of gradual conditioning and neuroplasticity.~Session 4: common ways to decrease nervous system sensitivity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise protocol for each group will be identical and modeled after the Back to Fitness program. This program will consist of a 5-10-minute cardiovascular warm-up of walking in place or riding an exercise bike. Next is a 15-minute circuit consisting of 10 different general exercises for 1-minute each. Finally, a 5-minute cool down will consist of light stretching and trunk range of motion exercises. Each exercise will be tailored as easy, medium, or hard depending on the individual patient's tolerance. This program has been shown to be equally as effective as motor control exercises for long-term outcomes in patients with non-specific LBP.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The exercise protocol for each group will be identical and modeled after the Back to Fitness program. This program will consist of a 5-10-minute cardiovascular warm-up of walking in place or riding an exercise bike. Next is a 15-minute circuit consisting of 10 different general exercises for 1-minute each. Finally, a 5-minute cool down will consist of light stretching and trunk range of motion exercises. Each exercise will be tailored as easy, medium, or hard depending on the individual patient's tolerance. This program has been shown to be equally as effective as motor control exercises for long-term outcomes in patients with non-specific LBP.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Education
Description: Weekly education sessions lasting approximately 30 minutes each, once a week for four weeks.~Session 1 will include a basic overview of the anatomy of the spine.~Session 2 will discuss an overview of stress symptoms to include hypervigilance, avoidance, and re-experiencing.~Session 3 will cover common recommendations delivered in stress education: the do's and don'ts of stress management.~Session 4: review and mindfulness.
Study: NCT04363996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Bioactive Restorative Material
Description: Filling material

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: New Bioactive Restorative Material
Description: Filling material
Study: NCT03948997

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL)
Description: Pulsed dye laser (PDL, 595nm) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis
Study: NCT01128075

Intervention type: DEVICE
Intervention: RebiSmart™
Description: Electronic self-injection device (RebiSmart™) to inject Rebif®

Intervention type: DEVICE
Intervention: RebiSmart™
Description: Electronic self-injection device (RebiSmart™) to inject Rebif®
Study: NCT04212195

Intervention type: GENETIC
Intervention: Next generation sequencing
Description: Saliva samples
Study: NCT02793895

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic SEEQ™ mobile cardiac telemetry system
Description: The SEEQ™ system consists of a wearable sensor which is a single-lead, low-profile, peel-and-stick device applied over the anterior left chest wall of the subject. The wearable patch is designed for one-time use only and cannot be re-applied if removed. Each sensor provides up to 7.5 days of monitoring. Subjects randomized to the intervention group will undergo 30 days of continuous cardiac rhythm monitoring with the SEEQ™ device at the time of randomization. At 6+/-1 months, subjects randomized to the intervention group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: For subjects randomized to the usual care group, no protocol-mandated cardiac rhythm monitoring will be performed. However, subjects in the control group may undergo rhythm monitoring during the study period if their treating physicians deem that there is a clinical indication to so do. At 6+/-1 months, subjects randomized to the usual care group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device or the CardioSTAT (Icentia. Inc) cardiac rhythm monitoring device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device
Description: The CardioSTAT device is a wearable adhesive cardiac rhythm monitoring system which is low-profile, water-resistant, and is adhered onto the skin surface with 2 electrodes. This wearable adhesive device is designed for one-time use only. Each CardioSTAT device will provide 14 days of cardiac rhythm monitoring. For subjects randomized to the intervention group who will be monitored by the CardioSTAT device, they will receive 28 days of continuous cardiac rhythm monitoring.
Study: NCT03482141

Intervention type: DEVICE
Group type: OTHER
Intervention: Whole Exome Sequencing (WES)
Description: The Investigators will enroll pregnant women with fetal anomalies detected by ultrasound. Patients will be approached by a maternal-fetal specialist, who has counseled the patient regarding the fetal anomaly that has been detected. Written informed consent will be obtained by the study prenatal genetic counselor. Many patients will have undergone prenatal diagnostic testing in an outside laboratory; in such cases, cells or extracted DNA from the original fetal sample will be used for the purpose of this study. The consent process for prenatal WES will include pre-test counseling and the option of choosing whether or not to receive uncertain results and secondary findings. After conducting whole exome sequencing, the findings will be shared with the parent(s). Routine medical care will be provided to patients. The research will study the effectiveness of sequencing as a tool for providing genetic information to parents when a prenatal study reveals a fetus with a structural anomaly.
Study: NCT02599116

Intervention type: OTHER
Group type: OTHER
Intervention: Bio-specimen collection
Description: Collection of bio-specimens (fecal sample) at 3 different time points One pre-operative collection, Two post-operative collections

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Completion of lifestyle and food questionnaires (2) at each bio-specimen collection timepoint
Study: NCT04562415

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Repetitive Transcranial Magnetic Stimulation Therapy
Description: 10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and inhibitor rTMS was applied with a frequency of 1 Hz consisting of 1200 pulses for 20 minutes. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Continuous Theta Burst Stimulation Therapy
Description: 10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and cTBS was administered for a total of 600 pulses consisting of 3 burst stimulations of 50 Hz repeated every 200 milliseconds for 40 seconds. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Continuous Theta Burst Stimulation Therapy
Description: 10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and sham cTBS was administered for a total of 600 pulses consisting of 3 burst stimulations of 50 Hz repeated every 200 milliseconds for 40 seconds. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
Study: NCT02439944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine mouthspray
Study: NCT02979457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Awareness of degree of worry
Description: degree of worry is a definition made for this project. It is roothed in coping psychology but has been influenced by the construct of self-rated health. Will blinding of DOW have an effect on triage outcome.
Study: NCT01264640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin and Clopidogrel
Description: Intake of 500 mg Aspirin on day 1. Intake of 600 mg Clopidogrel on day 28. Blood collection for the measurement of platelet inhibition, platelet counts and BDNF, TGF-beta, 5-HT concentrations in peripheral blood on day 1 (before intake of 500 mg Aspirin), day 2 (24 hours after intake of 500 mg Aspirin), day 28 (before intake of 600 mg Clopidogrel), day 29 (24 hours after intake of 600 mg Clopidogrel).
Study: NCT03944395

Intervention type: OTHER
Group type: OTHER
Intervention: Assisted Partner Notification Services
Description: Three options for partner Notification services; contract referral, provider referral and dual referral
Study: NCT02107885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1971
Description: 6 subjects in each group will receive DS-1971.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 subjects in each group will receive placebo.
Study: NCT00738296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe (+) simvastatin
Description: Patients will receive the combination of ezetimibe/simvastatin 10/20 mg o.d. with the possibility to increase the dose to 10/40 mg o.d. for 1 year. Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: Patients will receive 40mg od. With the possibility to escalate the dose to 80 mg o.d. if therapeutic goals not attained; for 1 year. Tablets
Study: NCT00951548

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: Probiotic blend of 8 different strains of lactobacilli and bifidobacteria, dosed at 900 billion bacteria/sachet). Dosage regimen is 2 sachets b.i.d. for 8 weeks
Study: NCT03754803

Intervention type: OTHER
Intervention: HIV Symptom Distress Module Questionnaire
Description: The Symptom Distress Module is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment.

Intervention type: OTHER
Intervention: HIV Symptom Distress Module Questionnaire
Description: The Symptom Distress Module is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment.
Study: NCT00738296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pravastatin
Description: Patients will receive pravastatin 40 mg o.d. with the possibility to add up 10mg of ezetimibe daily if LDL-C goal is not achieved; for 1 year. Tablets
Study: NCT03333603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: esomeprazole 40mg /tab oral Day1-Day14 then 40mg/2 tab oral Day15-Day56
Study: NCT03928925

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bougie
Description: disposable tracheal tube introducer of approximately 70 cm in length

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Tube with Stylet
Description: endotracheal tube preloaded with a removable, malleable stylet